Open Peer Review on Qeios

Saracatinib

National Cancer Institute

Source

National Cancer Institute. <u>Saracatinib</u>. NCI Thesaurus. Code C48378.

An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinasemediated osteoclast bone resorption.